MX2011012576A - Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo. - Google Patents

Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo.

Info

Publication number
MX2011012576A
MX2011012576A MX2011012576A MX2011012576A MX2011012576A MX 2011012576 A MX2011012576 A MX 2011012576A MX 2011012576 A MX2011012576 A MX 2011012576A MX 2011012576 A MX2011012576 A MX 2011012576A MX 2011012576 A MX2011012576 A MX 2011012576A
Authority
MX
Mexico
Prior art keywords
highly concentrated
produce
immunoglobulin preparation
subcutaneous use
concentrated immunoglobulin
Prior art date
Application number
MX2011012576A
Other languages
English (en)
Spanish (es)
Inventor
Wolfgang Teschner
Hans-Peter Schwarz
Harald Arno Butterweck
Azra Pljevljakovic
Theresa Friederike Bauer
Bernhard Koelbl
Nebojsa Nikolic
Gerhard Poelsler
Johanna Kindermann
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011012576(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int filed Critical Baxter Int
Publication of MX2011012576A publication Critical patent/MX2011012576A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Water Supply & Treatment (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2011012576A 2009-05-27 2010-05-27 Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo. MX2011012576A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18160609P 2009-05-27 2009-05-27
PCT/US2010/036430 WO2010138736A2 (en) 2009-05-27 2010-05-27 A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

Publications (1)

Publication Number Publication Date
MX2011012576A true MX2011012576A (es) 2012-05-08

Family

ID=42335649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012576A MX2011012576A (es) 2009-05-27 2010-05-27 Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo.

Country Status (18)

Country Link
US (5) US8546548B2 (https=)
EP (3) EP3708581A3 (https=)
JP (1) JP5341252B2 (https=)
KR (1) KR101464032B1 (https=)
CN (1) CN102459331B (https=)
AR (1) AR076607A1 (https=)
AU (6) AU2010253830B2 (https=)
BR (1) BRPI1012082B1 (https=)
CA (1) CA2763138A1 (https=)
CL (2) CL2011002996A1 (https=)
CO (1) CO6480954A2 (https=)
EA (1) EA023382B1 (https=)
HK (1) HK1200843A1 (https=)
MX (1) MX2011012576A (https=)
MY (1) MY157239A (https=)
SG (1) SG176256A1 (https=)
TW (1) TWI445714B (https=)
WO (1) WO2010138736A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
TWI445714B (zh) * 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
EP3309168A1 (en) 2009-08-06 2018-04-18 F. Hoffmann-La Roche AG Method to improve virus removal in protein purification
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
FR2962650B1 (fr) * 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
US20120076779A1 (en) 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
SG11201400233TA (en) 2011-08-26 2014-08-28 Baxter Int Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
KR101956585B1 (ko) 2011-09-24 2019-03-11 체에스엘 베링 게엠베하 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법
US9075069B2 (en) 2011-12-13 2015-07-07 Baxter International Inc. Measurement of autoantibodies at low conductivity with increased sensitivity
CN102532307B (zh) * 2012-02-22 2013-06-12 成都蓉生药业有限责任公司 一种制备人免疫球蛋白的方法
TWI629283B (zh) * 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
JP6224586B2 (ja) * 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
WO2015073633A1 (en) * 2013-11-15 2015-05-21 Genentech, Inc. Methods for viral inactivation using eco-friendly detergents
WO2016161418A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang A method of manufacturing an afod intra venous injection from fraction iv
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
FR3081328B1 (fr) * 2018-05-24 2021-01-01 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
EA202192860A1 (ru) * 2019-04-18 2021-12-23 Янссен Байотек, Инк Сиалилированные гликопротеины
MX2024010855A (es) 2022-03-07 2024-09-11 Takeda Pharmaceuticals Co Produccion cromatografica de afinidad de productos clinicos de inmunoglobulina g (igg) humana.
CN117069836B (zh) * 2023-09-22 2024-08-27 武汉中生毓晋生物医药有限责任公司 一种抗人t细胞兔免疫球蛋白的制备方法
WO2025068923A2 (en) * 2023-09-26 2025-04-03 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (https=) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3929411A1 (de) 1988-09-22 1990-03-29 Siegfried Natterer Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
US4892826A (en) 1988-10-11 1990-01-09 Abbott Laboratories Process for the preparation of urokinase derivatives
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
AT402261B (de) 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
AT405739B (de) 1997-09-19 1999-11-25 Immuno Ag Verfahren zur reinigung von antithrombin iii
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
IL140155A (en) * 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
DK2270044T3 (en) * 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020098182A1 (en) 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
EP1463527A4 (en) 2001-10-04 2005-05-11 Protein Therapeutics Inc USE OF GAMMAGLOBULIN FOR THE TREATMENT OF IMMUNE-MEDIATED DISEASES
WO2005023867A1 (en) 2003-09-08 2005-03-17 Medical Research Council Method for the treatment or prophylaxis of tuberculosis
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
EP2522754B1 (en) 2007-08-13 2014-04-02 Baxter International Inc. IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease
CN101279246B (zh) * 2007-12-28 2011-07-27 华侨大学 一种嗜硫性磁性复合微球的制备方法和用此复合微球分离免疫球蛋白g的方法
AU2009236305B2 (en) 2008-04-15 2014-04-10 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
TWI445714B (zh) * 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法

Also Published As

Publication number Publication date
US8546548B2 (en) 2013-10-01
SG176256A1 (en) 2012-01-30
US9175068B2 (en) 2015-11-03
TW201107344A (en) 2011-03-01
KR20140014403A (ko) 2014-02-06
JP2012528190A (ja) 2012-11-12
US20190085064A1 (en) 2019-03-21
HK1200843A1 (en) 2015-08-14
US20220153823A1 (en) 2022-05-19
EP2762492A2 (en) 2014-08-06
AU2024203600A1 (en) 2024-06-20
EA023382B1 (ru) 2016-05-31
WO2010138736A3 (en) 2011-03-17
EA201171481A1 (ru) 2012-07-30
CL2013001673A1 (es) 2013-12-06
AU2016203542B2 (en) 2018-02-15
EP2435474A2 (en) 2012-04-04
AU2020204244B2 (en) 2022-08-18
AU2010253830A1 (en) 2011-12-15
EP3708581A3 (en) 2021-10-20
CA2763138A1 (en) 2010-12-02
CL2011002996A1 (es) 2012-10-19
AU2010253830B2 (en) 2016-03-03
CO6480954A2 (es) 2012-07-16
AU2020204244A1 (en) 2020-07-16
US10125189B2 (en) 2018-11-13
AU2016203542A1 (en) 2016-06-16
CN102459331B (zh) 2015-01-28
AU2022228125B2 (en) 2024-02-29
EP2762492A3 (en) 2015-03-18
JP5341252B2 (ja) 2013-11-13
BRPI1012082A2 (pt) 2019-04-02
US20160244512A1 (en) 2016-08-25
WO2010138736A2 (en) 2010-12-02
MY157239A (en) 2016-05-13
US20100330071A1 (en) 2010-12-30
AU2018200548A1 (en) 2018-02-15
US20140030252A1 (en) 2014-01-30
TWI445714B (zh) 2014-07-21
CN102459331A (zh) 2012-05-16
KR101464032B1 (ko) 2014-11-27
BRPI1012082B1 (pt) 2022-08-16
AU2022228125A1 (en) 2022-09-29
US11242380B2 (en) 2022-02-08
AR076607A1 (es) 2011-06-22
EP3708581A1 (en) 2020-09-16
AU2018200548B2 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
MY157239A (en) A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MY150542A (en) Cmet inhibitors
MX2013001580A (es) Composiciones que comprenden un polipeptido que tiene actividad de incremento celulolitico y un licor, y usos de las mismas.
NZ612647A (en) Anti-bcma antibodies
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
MY159252A (en) Process for the preparation of dopo-derived compounds and compositions thereof
MX357677B (es) Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas.
MX2011012523A (es) Esteres cetalicos de anhidropentitoles y usos de los mismos.
MX2011008621A (es) Proceso para la purificacion de lipopeptidos.
PT2382198E (pt) Processos e intermediários para a preparação de um inibidor macrocíclico de protease do vhc
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
TW201129620A (en) New formaldehyde scavengers
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
DE602007008731D1 (de) Verfahren zur herstellung einer l-aminosäure unter verwendung eines bakteriums der familie enterobacteriaceae mit abgeschwächter expression des rspab-operons
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
NZ600978A (en) Vaccine compositions
MX2010009931A (es) Proceso para la preparacion de 2-amino-2-[2-(4-c3-c21-alquil-fenil )-etil]-propano-1,3-dioles.
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
IN2014DN03245A (https=)
AU2012248013B2 (en) Intermediate for synthesizing caspofungin and preparation method therefor
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
MX2010003056A (es) Polimorfos de valomaciclovir.
MX2010003873A (es) Aditivo para polimeros y proceso para la produccion del mismo.

Legal Events

Date Code Title Description
FG Grant or registration